Considering the failure of hyperimmune globulin in most randomized controlled clinical trials to improve clinical outcomes in influenza A [137,150] or respiratory syncytial virus [148] and given the non-availability of randomized clinical trials on CP for any other viral disease, it is not wrong to assume that 1–2 U of CP in COVID-19 will be clinical relevance. The gene discussed is CP; the disease is COVID-19.